Kornimate/medical-research-clean huggingface dataset:
reproductive health outcomes in young patients with ovarian cancer after surgical treatment: a retrospective study

Conditions: Ovarian Cancer

Summary: ovarian cancer (oc) is the second commonest gynecological cancer with an overall incidence of 1.4% , associated with high mortality rate , there are three major types of ovarian cancers: epithelial ovarian carcinomas, germ cell tumors, and stromal cell tumors . ovarian cancer directly affects fertility, as treatment consists of surgical removal of the reproductive system and/or exposure to gonadotoxic agents. however, patients in early stages who meet established criteria can be treated with fertility-sparing surgeries and reach equivalent oncological results to those of traditional treatments. fertility preservation techniques such as cryopreservation of oocytes, embryos and ovarian tissue may also be offered in some situations. ovarian cancer (oc) has a high mortality rate and usually presents late in advanced stage, which poses challenges to management. better understanding of the disease biology and application of radical surgery (rs) to achieve no visible residual tumor, alongside with chemotherapy, may lead to longer survival amongst these patients. our purpose is to find out the fertility and survival rates of women with overian cancer in reproductive women who underwent surgical intervention. radical surgery for overian cancer is one of the most challenging procedures in gynecologic oncology surgery.


Eligibility criteria:
inclusion criteria: 1. women in reproductive age 18-45 yrs 2. localized ovarian cancer 3. patients undergoing surgical intervention exclusion criteria: 1- patients who refuse to participate in the study. 2 - children and manupausl women 3 - diffuse peritoneal ,enteric and mesenteric disease or very poor patient 's performance status 4 -patients who were treated with chemotherapy only and not operated
peace: ivy, thyme and cisti extract (phytus) efficacy in acute cough

Conditions: Cough; Common Cold

Summary: the purpose of this study is to investigate the efficacy of phytus in acute cough

common colds are the most frequently encountered human diseases worldwide. common cold is a conventional term used for mild upper respiratory illnesses, which comprises a heterogeneous group of self-limited diseases caused by numerous viruses. the frequency is age-specific with fewer episodes in adults than in younger children. cough due to the common cold is probably the most common cause of acute cough. in a significant subset of patients with "post infectious" cough, the etiology is probably an inflammatory response triggered by a viral upper respiratory infection (ie, the common cold). the resultant sub-acute or chronic cough can be considered to be due to an upper airway cough syndrome, previously referred to as postnasal drip syndrome. thyme leaf (thymus vulgaris) expels phlegm and relieves congestion . it is antiseptic and an immune stimulant. the primary chemical constituents of thyme include essential oil (borneol, carvacrol, cymol, linalool, thymol), bitter principle, tannin, flavonoids (apigenin, luteolin), saponins, and triterpenic acids. thyme warms and stimulates the lungs, expels mucus, and relieves congestion. it also helps deter bacterial, fungal, and viral infections. the thymol content of thyme works as an expectorant and cough suppressant and is frequently used in cough syrups.

Eligibility criteria:
inclusion criteria: * cough attributed to urti such as the common cold * moderate to severe day cough according to questionnaire (score at least 3 on all 3 questions relating to day cough) considering the day prior to enrollment. * moderate to severe night cough score according to questionnaire (score at least 3 of 2 of the three questions relating to the evaluation of nocturnal cough exclusion criteria: * diagnosis of chronic cardiac condition, or cystic fibrosis or any anatomical respiratory tract anomalies, * received antihistamines or any cough medicine the day prior to study entry,known sensitivity to any component of phytus

Keywords: cough thyme cisti ivy leaves
predictive gene profiles and dynamic measurement of treatment response in metastatic non-small cell lung cancer

Conditions: Metastatic Nonsmall Cell Lung Cancer

Summary: the study aims include: * exploring potential predictive molecular profiles to immunotherapy/chemotherapy * investigating the role of circulating tumor dna as a dynamic biomarker during immunotherapy/chemotherapy * identifying possible resistance mechanisms to immunotherapy/chemotherapy materials and methods: approximately 150 patients diagnosed with metastatic nsclc assigned for immunotherapy or chemotherapy will be candidates for inclusion during a 1-2 years period. a comprehensive molecular profiling will be made from the diagnostic biopsy. before every treatment-cycle a blood sample will be taken to quantify ctdna. at time of progressive disease during/after first line treatment, patients will be asked to participate in a new biopsy and a comprehensive molecular profiling will be performed. the tissue and blood samples collected will be stored in a biobank. clinical data will be collected to perform a comprehensive database. analysis: potentially predictive molecular profiles for immunotherapy/chemotherapy will be found by comparison of treatment outcome for patients with specific molecular characteristics. through quantification of ctdna during treatment and upon progression, the role of ctdna as a dynamic biomarker will be further strengthened. differences in molecular profiles pre- and post-treatment may reveal resistance mechanisms to treatment. molecular profiling on progression can be valuable in second-line treatment guidance.


Eligibility criteria:
inclusion criteria: * age \> 18 years * able to understand and read danish * who performance status 0-2 * acceptable organ function (liver/kidney/heart) for treatment * the disease has to be: evaluable or measurable according to recist/irecist accessible for biopsy metastatic or not suitable for curative intended treatment exclusion criteria: * other active cancers * contraindications for systemic therapy * alk-positive, ros-1 or egfr mutations

Keywords: liquid biopsy genomic profiling ctdna
physical therapy wound care modalities in patients with spinal cord injury (sci)

Conditions: Spinal Cord Injuries; Pressure Injuries

Summary: to examine the effects of physical therapist (pt) wound care modalities (pulsed wound irrigation (pwi) + electrical stimulation (es), pwi only, and es only) on wound healing in patients with spinal cord injuries (sci).

it is hypothesized that pwi + es will demonstrate the greatest rate of wound healing due to the combined effect of these treatments, which positively impact several aspects of the wound healing cascade. it is hypothesized that all patients will demonstrate improved quality of life from receiving wound care treatments by physical therapists due to individualized education and treatments which engage patients in their wound healing process and promote self-efficacy.

Eligibility criteria:
inclusion criteria: * currently enrolled at inpatient rehabilitation at carolinas rehabilitation charlotte * diagnosis of spinal cord injury and concomitant pressure injury to sacrum or ischium * agreeable to wound care treatment by physical therapist (pt) * able to perform informed consent * over 18 years of age * physician order for pt wound care evaluation and treatment * bates-jensen wound assessment tool (bwat) \>31 on initial evaluation exclusion criteria: * pain which limits ability to tolerate wound care treatments * unable to perform informed consent * pregnancy * bates-jensen wound assessment tool (bwat) \<30 on initial evaluation

Keywords: wound care physical therapy pulsed wound irrigation electrical stimulation
anxiety about casual exposure to food allergens

Conditions: Food Allergy

Summary: living with food allergy may result in anxiety and reduced quality of life. food allergic patients and their families are often concerned about casual exposure with the offending allergen through skin contact or being near the offending food, which is actually very low risk. this concern can limit social activities and increase stress. the aim of this study is to provide a behavioral intervention consisting of having peanut/tree nut allergic patients hold a cup with a peanut or tree nut to which the patient is allergic to and touching it. the goal is to reduce anxiety about casual exposure to food allergens and improve quality of life for patients with food allergies and their families.

the purpose of the present study is to determine if having patients (ages 9-17) who are peanut and/or tree nut allergic, and endorse anxiety/discomfort about non-ingestion exposure, hold and touch their offending allergen in addition to education leads to reduced discomfort for both patient and caregiver compared to education alone. the primary outcome measure is immediate differences in the score obtained on a child-reported scale in response to a question assessing how worried the patient is about the thought of being near or touching peanut or tree nut from pre-intervention to immediate post-intervention when compared between an intervention (education and touching) and a control group (education only). secondary outcome measures include: difference between and within groups of child-reported scales regarding questions assessing patients worry regarding casual exposure immediately and one month post intervention within and between groups, differences between and within groups on a parent-reported scale regarding parental worry about casual exposure to food allergen immediately and one month post intervention within and between groups, differences between and within groups on a parent-proxy measures regarding child worry about casual exposure to food allergen immediately and one month post intervention within and between groups, improvement in child anxiety and parent-proxy measures of anxiety from pre-intervention to one month post-intervention within and between groups and improvement in parent-proxy measures of quality of life from pre-intervention to one month post-intervention within and between groups.

Eligibility criteria:
inclusion criteria: * age: 9 years to 17.5 years * patient seen in the outpatient clinic (no inpatients). * patient and or caretaker endorses anxiety about being in proximity with or touching peanut * patients must have been diagnosed with a peanut and or tree nut allergy exclusion criteria: * patients and caregiver(s) without ability to understand the study, as determined by either: a previously diagnosed cognitive disability or inability to repeat the study protocol at the time of consent.

Keywords: food allergy anxiety casual exposure peanut hypersensitivity tree nut hypersensitivity adolescents
fibro-inflammatory progression from acute to chronic pancreatitis

Conditions: Pancreatitis; Acute Pancreatitis; Recurrent Pancreatitis; Chronic Pancreatitis; Inflammation; Fibrosis

Summary: observational prospective study evaluating the developement of chronic pancreatitis based on imaging modalities as well as biochemical markers of inflammation, fibrosis and oxidative stress.

chronic pancreatitis (cp) represents the end-stage of a continuous disease process evolving from acute pancreatitis (ap), over recurrent acute pancreatitis (rap). due to the irreversible nature of cp, early detection and prevention is key. the study uses state-of-the-art imaging modalities as well as biochemical markers of to evaluate fibrosis progression in patients with pancreatitis. the included participants have either first time ap, rap, early cp with preserved pancreatic exocrine and endocrine function or end-stage cp with exocrine insufficiency. included patients will be followed prospectively for 15 years with advanced mri and contrast enhanced eus with elastography, assessment of endocrine and exocrine pancreatic function, biochemical and nutritional assessment, and evaluation of pain processing using quantitative sensory testing. blood for a biobank will be obtained. the purpose of the biobank is to allow analyses of potential biomarkers for the progression of disease eventually leading to cp.

Eligibility criteria:
inclusion criteria: * patients with cp (n=50) of any aetiology except gallstone induced cp: cp will be diagnosed based on mannheim criteria . * cohort 2: patients with their first attack of ap of any aetiology except gallstone induced ap (n=50). the revised atlanta criteria for acute pancreatitis will be used as diagnostic criteria. * cohort 3: patients with rap (n=50) except gallstone induced rap. rap is defined as two or more cases of ap as diagnosed by the revised atlanta criteria. exclusion criteria:
study to investigate the efficacy and safety of sc0023, in adults with refractory or unexplained chronic cough

Conditions: Chronic Cough

Summary: this is a randomized, double-blind, placebo controlled cross-over study to investigate the efficacy and safety of sc0023 (an oral spray of magnesium based alkaline hypertonic divalent salt) in adults with refractory or unexplained chronic cough over 14 days. approximately 20 participants being enrolled and randomized into the study.


Eligibility criteria:
inclusion criteria: * males and females between 18-80 years * capable of giving signed informed consent * diagnosed with rcc (including unexplained chronic cough) for at least 6 months and at least 4 coughs per hour on average during awake hours at screening. * score ≥ 40 mm on cough severity vas at screening. * normal fev/fvc * women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose. exclusion criteria: * current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history. * diagnosis of chronic obstructive pulmonary disease (copd) bronchiectasis, idiopathic pulmonary fibrosis or uncontrolled asthma. * respiratory tract infection within 4 weeks before screening. * history of malignancy in the last 5 years. * history of alcohol or drug abuse within the last 3 years. * opioid use in last 7 days of screening. * history of a positive serologic test for, hepatitis b virus surface antigen, or hepatitis c virus. * previous participation in clinical trial in last 30 days or 6-half lives of test drug activity. * use of prohibited medications anti-tussive therapy, gabapentin, pregabalin, baclofen, tricyclics, systemic corticosteroids, ace inhibitors, beta blockers. * use of dietary supplements containing magnesium for the duration of the study. * history of myocardial infarction or other cardiac disorders. * history of any clinically significant or psychiatric condition that in the eyes of the investigator or designee would not be suitable for this study. or if in the eyes of the investigator or designee may prove noncompliant to study procedures. * spouses or other family members with a chronic cough in household or * living and working in an excessively loud workplace (e.g. building site)
use of analgesic treatment to reduce signs of pain in patients with disorders of consciousness.

Conditions: Disorders of Consciousness; Severe Brain Injury; Post-comatose Non-communicative Patients; Vegetative State; Minimally Conscious State

Summary: the purpose of this study is to characterize and improve pain and nociception management in patients with disorders of consciousness (doc). this project is divided into two phases, a first phase to evaluate pain level and a second phase which consist of a clinical trial to evalute pain medication efficacy. the main aim is to evaluate the use of the nociception coma scale-revised (ncs-r) and its cut-off score (i.e., 5) as an assessment and management tool to define guidelines for managing pain in patients with doc. in this double-blind, placebo-controlled clinical study, we will evaluate the use of analgesic treatments in reducing pain in subacute/chronic patients. the project will also allow us to validate the ncs-r cut-off score defined previously.

the study will be performed within one week (i.e, 7 days) and consists of two phases: * phase 1 "patients selection (d0)": patients will be assessed by the ncs-r during experimental stimulation (rest, tactile, noxious) and mobilizations (physiotherapy). patients with potential pain will be included in the phase 2. * phase 2 "analgesic administration (d1 and d2)": double-blind placebo-controlled randomized clinical trial on potential responders identified in phase 1. a medical doctor of our team will suggest to the physician in charge to prescribe the dedicated medication. one placebo and one real treatment will be administered on day 1 and 2 by the nurses at least half-hour before the physiotherapy. randomization between day 1 and 2 will be applied at that time. for each day of phase 1 and 2, several assessments will be performed: ncs-r, crs-r and spasticity assessment.

Eligibility criteria:
inclusion criteria: * have had an acquired brain injury with a loss of consciousness \> 28 days (patients) or have no history of previous brain injury (healthy controls) * legally authorized surrogate available to provide informed consent. * diagnosis of vegetative/unresponsive (vs/uws) or minimally conscious state (mcs) or emergence of the minimally conscious state without communication (emcs; as defined by the crs-r, see above). * medically stable (i.e., no systemic illness or disease). * patients with ncs-r score during mobilization above or equal to the previously determined cut-off score or ncs-r scores during mobilization equivalent to ncs-r score obtain during nociceptive stimulation will be included in the second phase of the study (i.e. d1 and d2). exclusion criteria: * history of developmental, neurologic, or major psychiatric disorder resulting in functional disability. * contraindication or unwillingness to discontinuing sedating and centrally-active drugs (benzodiazepine, long-acting sedating drugs) within 48 hours of assessment. * upper limb contusions, fractures or flaccid paralysis. * uncontrolled epilepsy and already on level 1 drugs

Keywords: nociception pain disorder of consciousness nociception coma scale revised
the clinical features of combined central and peripheral demyelination

Conditions: Combined Central and Peripheral Demyelination Disease

Summary: the investigators conduct this study to clarify the clinical features and to evaluate the prevalence of anti-nodal/paranodal antibodies of patients with combined central and peripheral demyelination (ccpd) .

the investigators will review the clinical manifestation, laboratory test results, electrophysiological examination and neuroimaging findings of patients with ccpd. and we will detect antibodies to aquaporin 4(aqp4), myelin oligodendrocyte glycoprotein (mog), neurofascin-155 (nfasc155), neurofascin-186 (nfasc186), and myelin-associated glycoprotein (mag) in patients with ccpd.

Eligibility criteria:
inclusion criteria: 1. t2 high-signal intensity lesions in the brain or spinal cord on mri, or visual-evoked potentials(veps) abnormalities. 2. conduction delay, conduction block, temporal dispersion or f-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (ncs). exclusion criteria: 1. infectious diseases(e.g., human t lymphocyte trophic virus type1-associated myelopathy, syphilis, neuroborreliosis, hiv infection or progressive multifocal leukoencephalopathy) 2. pre-existing inflammatory diseases (e.g., sarcoidosis, behçet's disease, sjögren's syndrome, vasculitis or other collagen diseases) 3. mitochondrial disease 4. metabolic/toxic diseases (e.g., vitamin deficiency, amyloidosis, chronic alcoholism, diabetes mellitus or subacute myelo-opticoneuropathy due to clioquinol intoxication 5. cervical spondylotic myelopathy 6. syringomyelia 7. spinocerebellar degeneration 8. multiple myeloma, other tumors 9. inherited diseases (e.g., leucodystrophies) 10. cerebrovascular disease 11. non-specific lesions on t2-weighted mri (e.g., leucoaraiosis).

Keywords: ccpd clinical features antibody
kinesio-taping versus pelvic floor exercise for post colonoscopy coccydynia

Conditions: Musculoskeletal Pain

Summary: forty-two patients, with coccydynia following colonoscopy were selected from kasr el-aini teaching hospital, with age ranged from 25-45 years. patients were randomly assigned to the control or experimental groups. the patients in the three groups completed 3-weeks 3 sessions per week for traditional physical therapy treatment consisting of stretching exercise for the piriformis and iliopsoas muscles, clamshell exercise, seat cushioning and seat kitz. experimental group i received kinsiotaping techniques in addition to the traditional physical therapy. while experimental group ii received pelvic floor exercise in the form of reverse kegel exercise or pelvic pulges, in addition to conventional therapies. pain intensity were evaluated by numerical rating scale as a primary out come measure, and oswestry disability index was used as a secondary out come measure.


Eligibility criteria:
inclusion criteria: * patients suffering from pain in or around the coccyx, following colonoscopy procedures. * age group ranging from 38-58 years old. exclusion criteria: * cancer. , - cysts in pelvic area. * pelvic fracture or recent trauma. * patient with pain in coccyx region referred from lumbar spine, pelvic floor muscles, degenerative disc, neoplasms, bony spurs, or infections.

Keywords: pelvic floor exercise coccydynia
evaluation of the rotational stability of the monofocal sisa implant following cataract surgery

Conditions: Cataract

Summary: a good efficacy as well as good rotary stability is expected with the ocular implant.


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * the patient must be available for 6 months follow-up * the patient it aged at least 18 years * patient requires surgery for cataracts with removal of the opacified natural lens and replacement with the sisa implant, according to standard procedure * the surgery is elective * the patient has clear and non-pathological corneas * the patient needs an implant strength (lio) between +10d and +30d * corneal astigmatism less than or equal to 1.50d in the eye to be operated (or cataract eye exclusion criteria: * the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * the patient is under safeguard of justice or state guardianship * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patient is pregnant or breastfeeding * the patient has other ocular comorbidities with poor visual acuity prognosis postoperatively * previous ocular trauma or surgery * dilation of the pupil \<7mm with mydriatic drugs * implantation with a rhexis that does not cover the optic of the implant by more than 1 cadranel